{"doi":"10.3389/fendo.2021.753185","title":"Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>In our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage of teriparatide obtained in the first 2 years would be maintained after the switch to denosumab.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>We switched patients who had completed 24-month daily teriparatide treatment to denosumab (switch group, n=18) and compared their BMD every 6 months up to 48 months with the group who continued to receive denosumab (denosumab group, n=16).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At 48 months, the lumbar spine BMD was significantly increased from baseline in both groups (denosumab: 10.4 ± 8.7%, p&amp;lt;0.001; switch: 14.2 ± 6.8%, p&amp;lt;0.001). However, a significant increase in femoral neck BMD from baseline occurred only in the switch group (11.2 ± 14.6%, p&amp;lt;0.05); denosumab (4.1 ± 10.8%). The total hip BMD increased significantly from baseline in both groups (denosumab: 4.60 ± 7.4%, p&amp;lt;0.05; switch: 7.2 ± 6.9%, p&amp;lt;0.01). Femoral neck BMD was significantly increased in the switch <jats:italic>versus</jats:italic> the denosumab group (p&amp;lt;0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In GIO patients with prior bisphosphonate treatment, the advantage of teriparatide may be maintained after the treatment period. A continuous increase in BMD can be expected with teriparatide followed by denosumab.</jats:p></jats:sec>","journal":"Frontiers in Endocrinology","year":2021,"id":665076,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1736699,"name":"Yuji Nozaki","orcid":null,"position":1,"is_corresponding":false},{"id":1736701,"name":"Saki Okuda","orcid":null,"position":2,"is_corresponding":false},{"id":1736702,"name":"Masafumi Sugiyama","orcid":null,"position":3,"is_corresponding":false},{"id":1480148,"name":"Koji Kinoshita","orcid":"0000-0002-6203-2898","position":4,"is_corresponding":false},{"id":1736704,"name":"Masanori Funauchi","orcid":null,"position":5,"is_corresponding":false},{"id":1642721,"name":"Itaru Matsumura","orcid":null,"position":6,"is_corresponding":false},{"id":1600775,"name":"Yasuaki Hirooka","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>In our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage of teriparatide obtained in the first 2 years would be maintained after the switch to denosumab.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>We switched patients who had completed 24-month daily teriparatide treatment to denosumab (switch group, n=18) and compared their BMD every 6 months up to 48 months with the group who continued to receive denosumab (denosumab group, n=16).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At 48 months, the lumbar spine BMD was significantly increased from baseline in both groups (denosumab: 10.4 ± 8.7%, p&amp;lt;0.001; switch: 14.2 ± 6.8%, p&amp;lt;0.001). However, a significant increase in femoral neck BMD from baseline occurred only in the switch group (11.2 ± 14.6%, p&amp;lt;0.05); denosumab (4.1 ± 10.8%). The total hip BMD increased significantly from baseline in both groups (denosumab: 4.60 ± 7.4%, p&amp;lt;0.05; switch: 7.2 ± 6.9%, p&amp;lt;0.01). Femoral neck BMD was significantly increased in the switch <jats:italic>versus</jats:italic> the denosumab group (p&amp;lt;0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In GIO patients with prior bisphosphonate treatment, the advantage of teriparatide may be maintained after the treatment period. A continuous increase in BMD can be expected with teriparatide followed by denosumab.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34646240","pmcid":"PMC8503555","openalex_id":"https://openalex.org/W3202087077","authors":[],"funders":[],"total_grants":0,"fwci":1.6115,"citation_percentile":0.81888054,"influential_citations":0,"citation_trend":[{"year":2022,"count":4},{"year":2023,"count":3},{"year":2024,"count":2},{"year":2025,"count":4},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fendo.2021.753185","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34646240","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC8503555","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8503555","host_type":"repository"},{"url":"https://doaj.org/article/5bcdfa3a4cd8407293cdc58fcb23a0e9","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8503555","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8503555?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Bone health and osteoporosis research","Bone health and treatments","Bone Metabolism and Diseases"],"mesh_terms":["Denosumab","Aged","Diphosphonates","Female","Femur Neck","Glucocorticoids","Hip","Humans","Male","Middle Aged","Osteoporosis","Prospective Studies","Spine","Bone Density","Teriparatide","Bone Density Conservation Agents"],"keywords":["Teriparatide","Denosumab","Medicine","Osteoporosis","Urology","Bone mineral","Bisphosphonate","Femoral neck","Internal medicine","bone mineral density","Glucocorticoid-induced Osteoporosis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-13T05:51:05.823146Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}